Found 221 clinical trials
Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation (3AOD)
The rhythm disorders of Atrial Fibrillation (AF) require continuous treatment with anticoagulants to prevent stroke. The introduction of direct oral anticoagulants (DOACs) quickly supplanted the administration of anti-vitamin K (AVK) which presented an elevated risk of hemorrhage. However, the adherence of the treatments by the OAD is very poor, several …
- 0 views
- 04 Oct, 2022
- 1 location
Heparin vs Placebo for Cardiac Catheterization
Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.
- 0 views
- 26 Jan, 2021
- 2 locations
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown
- 0 views
- 23 Sep, 2021
- 1 location
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (CLOSURE-AF)
stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).
- 13 views
- 28 Feb, 2022
- 17 locations
Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (OCEAN)
of oral anticoagulant therapy after successful ablation to therapy with an aspirin per day.
- 216 views
- 07 Apr, 2022
- 54 locations
API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)
thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy for treating a documented index event of proximal deep venous thrombosis (DVT) (symptomatic or
- 34 views
- 04 Oct, 2022
- 71 locations
The Randomized OPTIMAL-ACT Trial
Despite the widespread adoption of recommended anticoagulation intensity ranges during percutaneous coronary intervention (PCI), there are limited randomized clinical trials testing specific targets for activated clotting times (ACT). The primary research hypothesis is that in the modern cardiac catheterization laboratory, where PCI procedural duration is relatively short, radial access with …
- 0 views
- 24 Mar, 2022
- 1 location
Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial
device can detect subclinical episodes of rapid atrial rate, which correlate with electrocardiographically documented AF. The net benefit of anticoagulant treatment is well established in patients with
- 0 views
- 11 Sep, 2021
- 1 location
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
patients with cardiovascular disease receiving antiplatelet and oral anticoagulant therapy who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) is non-inferior to PPI
- 1 views
- 24 May, 2021
- 1 location
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation (START)
> Primary Objective: • To determine the optimal time to initiate anticoagulation with a Non-Vitamin K Oral Anticoagulant (NOAC) after ischemic stroke in patients with non-valvular atrial fibrillation
- 142 views
- 08 Jun, 2022
- 14 locations